Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey
Journal of Tropical Pediatrics · 2024
DOI: 10.1093/tropej/fmae029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Tropical Pediatrics, 2024. Verfasst von Saliha Kanık-Yüksek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital, Ankara 06800, Turkey. Hauptthemen laut MEDLINE: Fosfomycin, Anti-Bacterial Agents, Administration, Intravenous, Bacteremia. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Current data on fosfomycin usage in children are limited. We present data on the clinical use of intravenous (IV) fosfomycin in children. Hospitalized patients who received ≥3 days of IV fosfomycin between April 2021 and March 2023 were analyzed retrospectively. Forty-three episodes of infection in 39 patients were evaluated. The mean age of the patients was 5.35 (10 days to 17.5 years) years, and 54% were male. Infections were hospital-acquired in 79% of the episodes. Indications for fosfomycin were urinary tract infection (35%), bacteremia (32.6%), catheter-related bloodstream infection (16.3%), soft tissue infection (4.7%), sepsis (4.7%), surgical site infection (2.3%), burn infection (2.3%), and pneumonia (2.3%). Klebsiella pneumoniae was identified in 46.5% of the episodes, and a pan-drug or extensive drug resistance was detected in 75% of them. Carbapenem was used before fosfomycin at significantly higher rates in K. pneumoniae episodes (P = .006). Most (88.5%) patients received fosfomycin as a combination therapy. Culture negativity was achieved in 80% of episodes within a median treatment period of 3 (2–22) days, which was significantly shorter in K. pneumoniae episodes (P < .001). Treatment-related side effects were seen in 9.3% of the episodes. Side effects were significant after 3 weeks of treatment (P = .013). The unresponsivity rate to fosfomycin was 23.3%. Nine (21%) of the patients who were followed up in the intensive care units mainly died because of sepsis (56%). IV fosfomycin is an effective agent in treating severe pediatric infections caused by resistant microorganisms. Fosfomycin can be used in various indications and is generally safe for children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital, Ankara 06800, Turkey.
- Department of Pediatric Infectious Disease, Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital, Ankara 06800, Turkey.
ORCID-Profile: Saliha Kanık-Yüksek, Ömer Güneş, Belgin Gülhan, Tuğba Erat, Hatice Kübra Konca, Seval Özen, Aysun Yahşi, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay
Zitieren
APA
Kanık-Yüksek, S., Güneş, Ö., Gülhan, B., Erat, T., Konca, H. K., Özen, S., Yahşi, A., Bayhan, G. İ., & Özkaya-Parlakay, A. (2024). Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey. Journal of Tropical Pediatrics. https://doi.org/10.1093/tropej/fmae029
Vancouver
Kanık-Yüksek S, Güneş Ö, Gülhan B, Erat T, Konca HK, Özen S, et al. Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey. Journal of Tropical Pediatrics. 2024. doi:10.1093/tropej/fmae029
BibTeX
@article{KankYksek2024,
author = {Kanık-Yüksek, Saliha and Güneş, Ömer and Gülhan, Belgin and Erat, Tuğba and Konca, Hatice Kübra and Özen, Seval and Yahşi, Aysun and Bayhan, Gülsüm İclal and Özkaya-Parlakay, Aslınur},
title = {Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey},
journal = {Journal of Tropical Pediatrics},
year = {2024},
doi = {10.1093/tropej/fmae029}
}
EUVIMED